Q1 2026 Medicure Inc Earnings Call Transcript
Key Points
- Medicure Inc (MCUJF) reported a significant increase in net revenue for Q1 2026, reaching CAD 7.9 million compared to CAD 5.5 million in Q1 2025.
- The company successfully reduced its net loss to CAD 406,000 from CAD 694,000 in the same quarter of the previous year.
- Revenue from ZYPITAMAG through the traditional insured channel increased significantly to CAD 1.3 million from CAD 519,000 in Q1 2025.
- The acquisition of Gateway Medical Pharmacy and West Olympia Pharmacy has created synergies and additional revenue channels for Medicure Inc (MCUJF).
- Medicure Inc (MCUJF) has received Fast Track designation for its investigational drug MC-1, which is in a phase III trial for PNPO deficiency, potentially leading to a priority review voucher worth significant value.
- AGGRASTAT revenue decreased to CAD 979,000 from CAD 1.7 million due to increased competition from generic alternatives.
- The company recorded a decrease in cash balance to CAD 1.5 million from CAD 3.8 million at the end of December 2025.
- Research and development expenses increased to CAD 865,000 from CAD 570,000, impacting the overall financial performance.
- The cost of goods sold increased to CAD 4.4 million from CAD 2.6 million, primarily due to the pharmacy business segment.
- Medicure Inc (MCUJF) continues to face access challenges for ZYPITAMAG through traditional insurer channels, necessitating reliance on direct distribution through Marley Drug.
Welcome to Medicureâs earnings conference call for the quarter ending March 31, 2026. My name is Holly and I will be your operator for todayâs call.
(Operator Instructions) Before we proceed, I would like to remind everyone that this presentation contains forward-looking statements relating to future results, events, and expectations, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements involve known and unknown risks and uncertainties, which could cause the companyâs actual results to differ materially from those in the forward-looking statements.
Such risks and uncertainties include, among others, those described in the companyâs most recent annual information form and Form 20-F. Later, we will conduct a question and answer session. Please note that this conference call is being recorded and todayâs date is May 25, 2026.
I would now like to turn the conference call over to Dr. Albert Friesen, Chief Executive Officer of Medicure Inc. Please go ahead, Dr. Friesen.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
